Jump to content

BC-LI-0186

From Wikipedia, the free encyclopedia
BC-LI-0186
Identifiers
  • 4-(2,3-dimethyl-5-oxo-4-propan-2-ylpyrazol-1-yl)-N-(2-phenoxyethyl)benzenesulfonamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27N3O4S
Molar mass429.54 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)N(N1C)C2=CC=C(C=C2)S(=O)(=O)NCCOC3=CC=CC=C3)C(C)C
  • InChI=1S/C22H27N3O4S/c1-16(2)21-17(3)24(4)25(22(21)26)18-10-12-20(13-11-18)30(27,28)23-14-15-29-19-8-6-5-7-9-19/h5-13,16,23H,14-15H2,1-4H3
  • Key:SQYWMHPZMHDCHP-UHFFFAOYSA-N

BC-LI-0186 is a compound that acts as an inhibitor of the GTPase enzyme leucyl-tRNA synthetase (LRS). This enzyme acts as part of the mTOR complex and acts as a leucine sensor which stimulates mTORC1 in the presence of leucine. BC-LI-0186 blocks the docking site for mTORC1 and thereby prevents the mTOR activation and increased protein synthesis which is usually triggered by branched-chain amino acids such as leucine, yet without inhibiting the separate catalytic activity of LRS.[1] This may have potential applications in the treatment of cancer,[2] and BC-LI-0186 has also been shown to promote muscle regeneration after injury.[3]

References

[edit]
  1. ^ Kim JH, Lee C, Lee M, Wang H, Kim K, Park SJ, et al. (September 2017). "Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction". Nature Communications. 8 (1): 732. Bibcode:2017NatCo...8..732K. doi:10.1038/s41467-017-00785-0. PMC 5622079. PMID 28963468.
  2. ^ Kim EY, Lee JG, Lee JM, Kim A, Yoo HC, Kim K, et al. (2019). "Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 11: 1758835919846798. doi:10.1177/1758835919846798. PMC 6535710. PMID 31205503.
  3. ^ Son K, You JS, Yoon MS, Dai C, Kim JH, Khanna N, et al. (April 2019). "Nontranslational function of leucyl-tRNA synthetase regulates myogenic differentiation and skeletal muscle regeneration". The Journal of Clinical Investigation. 129 (5): 2088–2093. doi:10.1172/JCI122560. PMC 6486340. PMID 30985292.